In a report released today, Gena Wang from Barclays maintained a Hold rating on Crispr Therapeutics AG (CRSP – Research Report), with a price ...

BofA analyst Alec Stranahan raised the firm’s price target on Crispr Therapeutics (CRSP) to $86 from $85 and keeps a Buy rating on the shares.

CRISPR Therapeutics AG (CRSP) closed at $39.41 in the latest trading session, marking a -0.76% move from the prior day.

CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of 61.74% and 252.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock ...

Stocks: Real-time U.S. stock quotes reflect trades reported through ... Sources: FactSet, Tullett Prebon Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange ...

If an investor was to purchase shares of CRSP stock at the current price level of $42.35/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock ...

On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product. We recently compiled a list of the Cathie Wood’s Stock ...

CRISPR Therapeutics AG (CRSP) stock price is 41.21 and CRISPR Therapeutics AG (CRSP) 10-day simple moving average is 41.52. CRISPR Therapeutics AG (CRSP) stock price is 41.21 and CRISPR ...